Skip to contentB
Bioforce Nanosciences Holdings, Inc.
B
BFNHBioforce Nanosciences Holdings, Inc. Q2 2022 · 10-Q
Revenue—
Net Income-$115.78K-$115.78KN/M vs Q2 2021 EPS Diluted$0.00$0.00— vs Q2 2021 Operating Cash Flowderived-$9,624N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bioforce Nanosciences Holdings, Inc. · CIK 1310488 · Engraved from SEC EDGAR
ended Jun 30, 2022 · filed Jul 27, 2022 · 27 d after period end